Fig 1.
Flow chart of patient follow up divided in the derivation and validation cohorts.
MTX, methotrexate; RA, rheumatoid arthritis; ACR, American College of Rheumatology; tREACH, treatment in Rotterdam Early Arthritis Cohort.
Table 1.
Baseline characteristics per cohort [12].
Table 2.
Prevalencey, univariable OR’s (95% CI) for potential predictors of 3 months DAS28>3.2 insufficient response for derivation and validation cohorts.
Table 3.
Prediction model and scores for 3 months MTX non-response (DAS28>3.2).
Fig 2.
ROC curves for the prediction models of MTX insufficient response (DAS28>3.2) in the derivation (left panel) and validation (right panel) cohorts.
Area under receiver operating characteristics curve was 0.80 (95%CI: 0.73–0.86) in the derivation cohort and 0.80 (95%CI: 0.69–0.91) in the validation cohort.
Table 4.
Diagnostic parameters for various risk score cut-offs predicting MTX insufficient response (3 months DAS28>3.2) in the derivation cohort.